The DOI matches its Crossref record; 180 of the 180 references it cites were found in a registry or an index.
Aberrant Signaling Pathways in Glioma
Open accessAbstract
Glioblastoma multiforme (GBM), a WHO grade IV malignant glioma, is the most common and lethal primary brain tumor in adults; few treatments are available. Median survival rates range from 12–15 months. The biological characteristics of this tumor are exemplified by prominent proliferation, active invasiveness, and rich angiogenesis. This is mainly due to highly deregulated signaling pathways in the tumor. Studies of these signaling pathways have greatly increased our understanding of the biology and clinical behavior of GBM. An integrated view of signal transduction will provide a more useful approach in designing novel therapies for this devastating disease. In this review, we summarize the current understanding of GBM signaling pathways with a focus on potential molecular targets for anti-signaling molecular therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
Identification of human brain tumour initiating cells
Singh, S. K., Hawkins, C., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., Henkelman, R. M., Cusimano, M. D., & Dirks, P. B. (2004) · Nature · doi:10.1038/nature03128 · Cited by 7,433
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
Notch Signaling: Cell Fate Control and Signal Integration in Development
Artavanis-Tsakonas, S., Rand, M. D., & Lake, R. J. (1999) · Science · doi:10.1126/science.284.5415.770 · Cited by 5,909
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Etienne-Manneville, S., & Hall, A. (2002) · Nature · doi:10.1038/nature01148 · Cited by 4,201
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650 · cited 7×
“The TCGA pilot project revealed that the frequency of genetic alterations in the RB signaling pathway was 77%, containing CDKN2A homozygous deletion or mutations (52%), CDKN2B (p15 INK4b ) homozygous deletion (47%), CDKN2C (p18 INK4c ) homozygous deletion (2%), CDK4 amplification (18%), CCND2 (cyclin D2) amplification…”
BackgroundInfluentialHigh Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
The GTPase superfamily: conserved structure and molecular mechanism
Bourne, H. R., Sanders, D. A., & McCormick, F. (1991) · Nature · doi:10.1038/349117a0 · Cited by 3,392
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“of p53 [114,115].”
ATM and related protein kinases: safeguarding genome integrity
Shiloh, Y. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1011 · Cited by 2,577 · cited 1×
“In response to ionizing radiation, cells activate the sensor kinases ATM, ATR, and DNA-PK, a DNA-dependent protein kinase [133,134] that phosphorylates multiple downstream mediators, including the checkpoint kinases Chk1 and Chk2 [135,136], resulting in cell-cycle checkpoint initiation and/or apoptosis.”
BackgroundIsolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma
Galli, R., Binda, E., Orfanelli, U., Cipelletti, B., Gritti, A., De Vitis, S., Fiocco, R., Foroni, C., Dimeco, F., & Vescovi, A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1364 · Cited by 2,570
Role of Transforming Growth Factor β in Human Disease
Blobe, G. C., Schiemann, W. P., & Lodish, H. F. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005043421807 · Cited by 2,427
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316
Angiogenesis: an organizing principle for drug discovery?
Folkman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2115 · Cited by 2,246
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
RAS oncogenes: the first 30 years
Malumbres, M., & Barbacid, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1097 · Cited by 1,902 · cited 1×
“The RAS gene family comprises four different genes that encode HRAS, NRAS, KRAS4A, and KRAS4B [149,150].”
BackgroundCancerous stem cells can arise from pediatric brain tumors
Hemmati, H. D., Nakano, I., Lazareff, J. A., Masterman-Smith, M., Geschwind, D. H., Bronner-Fraser, M., & Kornblum, H. I. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2036535100 · Cited by 1,817
Zhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626
NF-κB is a target of AKT in anti-apoptotic PDGF signalling
Romashkova, J. A., & Makarov, S. S. (1999) · Nature · doi:10.1038/43474 · Cited by 1,517
Chk1 and Chk2 kinases in checkpoint control and cancer
Bartek, J., & Lukas, J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00110-7 · Cited by 1,513
Genetic Pathways to Primary and Secondary Glioblastoma
Ohgaki, H., & Kleihues, P. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070011 · Cited by 1,497
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Marcello, J., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Sampson, J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2440 · Cited by 1,394
Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma
Van Meir, E. G., Hadjipanayis, C. G., Norden, A. D., Shu, H. K., Wen, P. Y., & Olson, J. J. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20069 · Cited by 1,372
DNA Damage-Induced Activation of p53 by the Checkpoint Kinase Chk2
Hirao, A., Kong, Y.-Y., Matsuoka, S., Wakeham, A., Ruland, J., Yoshida, H., Liu, D., Elledge, S. J., & Mak, T. W. (2000) · Science · doi:10.1126/science.287.5459.1824 · Cited by 1,285
Ausprunk, D. H., & Folkman, J. (1977) · Microvascular Research · doi:10.1016/0026-2862(77)90141-8 · Cited by 1,281
Genetic Pathways to Glioblastoma
Ohgaki, H., Dessen, P., Jourde, B., Horstmann, S., Nishikawa, T., Di Patre, P.-L., Burkhard, C., Schüler, D., Probst-Hensch, N. M., Maiorka, P. C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1337 · Cited by 1,270
Stott, F. J. (1998) · The EMBO Journal · doi:10.1093/emboj/17.17.5001 · Cited by 1,167
The Molecular Basis of Turcot's Syndrome
Hamilton, S. R., Liu, B., Parsons, R. E., Papadopoulos, N., Jen, J., Powell, S. M., Krush, A. J., Berk, T., Cohen, Z., Tetu, B., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503303321302 · Cited by 1,133
Neural Stem Cells and the Origin of Gliomas
Sanai, N., Alvarez-Buylla, A., & Berger, M. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043666 · Cited by 1,044
Schindler, G., Capper, D., Meyer, J., Janzarik, W., Omran, H., Herold-Mende, C., Schmieder, K., Wesseling, P., Mawrin, C., Hasselblatt, M., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0802-6 · Cited by 1,034
IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas
Watanabe, T., Nobusawa, S., Kleihues, P., & Ohgaki, H. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080958 · Cited by 1,027 · cited 2×
“signature of secondary GBMs as well as their precursor lesions [122-124].”
BackgroundSelf-citationINTERLEUKIN-6: From Basic Science to Medicine—40 Years in Immunology
Kishimoto, T. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115806 · Cited by 1,024
Ignatova, T. N., Kukekov, V. G., Laywell, E. D., Suslov, O. N., Vrionis, F. D., & Steindler, D. A. (2002) · Glia · doi:10.1002/glia.10094 · Cited by 992
Notch signalling regulates stem cell numbers in vitro and in vivo
Androutsellis-Theotokis, A., Leker, R. R., Soldner, F., Hoeppner, D. J., Ravin, R., Poser, S. W., Rueger, M. A., Bae, S.-K., Kittappa, R., & McKay, R. D. G. (2006) · Nature · doi:10.1038/nature04940 · Cited by 956
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
Stommel, J. M., Kimmelman, A. C., Ying, H., Nabioullin, R., Ponugoti, A. H., Wiedemeyer, R., Stegh, A. H., Bradner, J. E., Ligon, K. L., Brennan, C., et al. (2007) · Science · doi:10.1126/science.1142946 · Cited by 938 · cited 1×
“Redundant inputs drive and maintain downstream signaling [188].”
BackgroundCombined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice
Holland, E. C., Celestino, J., Dai, C., Schaefer, L., Sawaya, R. E., & Fuller, G. N. (2000) · Nature Genetics · doi:10.1038/75596 · Cited by 905
Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2
Kamijo, T., Weber, J. D., Zambetti, G., Zindy, F., Roussel, M. F., & Sherr, C. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8292 · Cited by 899
STAT3 activation is sufficient to maintain an undifferentiated state of mouse embryonic stem cells
Matsuda, T. (1999) · The EMBO Journal · doi:10.1093/emboj/18.15.4261 · Cited by 895
Wong, A. J., Bigner, S. H., Bigner, D. D., Kinzler, K. W., Hamilton, S. R., & Vogelstein, B. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.19.6899 · Cited by 849
Molecular mechanisms of glioma invasiveness: the role of proteases
Rao, J. S. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1121 · Cited by 847
Watanabe, K., Tachibana, O., Sato, K., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (1996) · Brain Pathology · doi:10.1111/j.1750-3639.1996.tb00848.x · Cited by 740
IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas
Nobusawa, S., Watanabe, T., Kleihues, P., & Ohgaki, H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0715 · Cited by 711
Self-citationHermanson, M., Funa, N. S., Hartman, M., Claesson, L., Heldin, C., Westermark, B., & Nistér, M. (1992) · PubMed · Cited by 705
Galanis, E., Buckner, J. C., Maurer, M. J., Kreisberg, J. I., Ballman, K., Boni, J., Peralba, J. M., Jenkins, R. B., Dakhil, S. R., Morton, R. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.622 · Cited by 694
Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.
Shinojima, N., Tada, K., Shiraishi, S., Kamiryo, T., Kochi, M., Nakamura, H., Makino, K., Saya, H., Hirano, H., Kuratsu, J., et al. (2003) · PubMed · Cited by 663
FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme
Cohen, M. H., Shen, Y. L., Keegan, P., & Pazdur, R. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0121 · Cited by 655
Fan, X., Khaki, L., Zhu, T. S., Soules, M. E., Talsma, C. E., Gul, N., Koh, C., Zhang, J., Li, Y.-M., Maciaczyk, J., et al. (2010) · Stem Cells · doi:10.1002/stem.254 · Cited by 651
MOLECULAR PATHOLOGY OF MALIGNANT GLIOMAS
Louis, D. N. (2006) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100043 · Cited by 648
Smith, J. S., Tachibana, I., Passe, S. M., Huntley, B. K., Borell, T. J., Iturria, N., O'Fallon, J. R., Schaefer, P. L., Scheithauer, B. W., James, C. D., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.16.1246 · Cited by 630
Cyclopamine-Mediated Hedgehog Pathway Inhibition Depletes Stem-Like Cancer Cells in Glioblastoma
Bar, E. E., Chaudhry, A., Lin, A., Fan, X., Schreck, K., Matsui, W., Piccirillo, S., Vescovi, A. L., DiMeco, F., Olivi, A., et al. (2007) · Stem Cells · doi:10.1634/stemcells.2007-0166 · Cited by 607
Ekstrand, A. J., Sugawa, N., James, C. D., & Collins, V. P. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4309 · Cited by 602
Insulin-like growth factors and cancer
Macaulay, V. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.65 · Cited by 601
van den Bent, M. J., Brandes, A. A., Rampling, R., Kouwenhoven, M. C. M., Kros, J. M., Carpentier, A. F., Clement, P. M., Frenay, M., Campone, M., Baurain, J.-F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5984 · Cited by 575
Reifenberger, G., Liu, L., Ichimura, K., Schmidt, E., & Collins, V. P. (1993) · PubMed · Cited by 560
The insulin-like growth factor I receptor: a key to tumor growth?
Baserga, R. (1995) · PubMed · Cited by 552
Charles, N., Ozawa, T., Squatrito, M., Bleau, A.-M., Brennan, C. W., Hambardzumyan, D., & Holland, E. C. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.01.001 · Cited by 550
Jackson, E. L., Garcia-Verdugo, J. M., Gil-Perotin, S., Roy, M., Quinones-Hinojosa, A., VandenBerg, S., & Alvarez-Buylla, A. (2006) · Neuron · doi:10.1016/j.neuron.2006.06.012 · Cited by 542
Heimberger, A. B., Hlatky, R., Suki, D., Yang, D., Weinberg, J., Gilbert, M., Sawaya, R., & Aldape, K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1737 · Cited by 516
CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas.
Schmidt, E., Ichimura, K., Reifenberger, G., & Collins, V. P. (1994) · PubMed · Cited by 508
Ligon, K. L., Huillard, E., Mehta, S., Kesari, S., Liu, H., Alberta, J. A., Bachoo, R. M., Kane, M., Louis, D. N., DePinho, R. A., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.009 · Cited by 501
DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme?
Durocher, D., & Jackson, S. P. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00201-5 · Cited by 500
Lokker, N. A., Sullivan, C. M., Hollenbach, S. J., Israel, M. A., & Giese, N. A. (2002) · PubMed · Cited by 491
Haas-Kogan, D., Shalev, N., Wong, M., Mills, G., Yount, G., & Stokoe, D. (1998) · Current Biology · doi:10.1016/s0960-9822(07)00493-9 · Cited by 477
Bruna, A., Darken, R. S., Rojo, F., Ocaña, A., Peñuelas, S., Arias, A., Paris, R., Tortosa, A., Mora, J., Baselga, J., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.023 · Cited by 472
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib
Haas-Kogan, D. A., Prados, M. D., Tihan, T., Eberhard, D. A., Jelluma, N., Arvold, N. D., Baumber, R., Lamborn, K. R., Kapadia, A., Malec, M., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji161 · Cited by 465
Stupp, R., Hegi, M. E., Neyns, B., Goldbrunner, R., Schlegel, U., Clement, P. M. J., Grabenbauer, G. G., Ochsenbein, A. F., Simon, M., Dietrich, P.-Y., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.6650 · Cited by 454
Neovasculature induced by vascular endothelial growth factor is fenestrated.
Roberts, W. G., & Palade, G. E. (1997) · PubMed · Cited by 446
Lee, J., Son, M. J., Woolard, K., Donin, N. M., Li, A., Cheng, C. H., Kotliarova, S., Kotliarov, Y., Walling, J., Ahn, S., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2007.12.005 · Cited by 429
Ohgaki, H. (2009) · Methods in Molecular Biology · doi:10.1007/978-1-60327-492-0_14 · Cited by 418
Corsten, M. F., Miranda, R., Kasmieh, R., Krichevsky, A. M., Weissleder, R., & Shah, K. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1045 · Cited by 406
CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.
Ueki, K., Ono, Y., Henson, J. W., Efird, J. T., von Deimling, A., & Louis, D. N. (1996) · PubMed · Cited by 404
Hirao, A., Cheung, A., Duncan, G., Girard, P.-M., Elia, A. J., Wakeham, A., Okada, H., Sarkissian, T., Wong, J. A., Sakai, T., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.18.6521-6532.2002 · Cited by 404
Furnari, F. B., Huang, H., & Cavenee, W. K. (1998) · PubMed · Cited by 395
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
Chang, S. M., Wen, P., Cloughesy, T., Greenberg, H., Schiff, D., Conrad, C., Fink, K., Robins, H. I., De Angelis, L., Raizer, J., et al. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-1444-0 · Cited by 395
Molecular targets of glioma invasion
Nakada, M., Nakada, S., Demuth, T., Tran, N. L., Hoelzinger, D. B., & Berens, M. E. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-6342-5 · Cited by 387
Self-citationReceptor tyrosine kinase signalling as a target for cancer intervention strategies.
Zwick, E., Bange, J., & Ullrich, A. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080161 · Cited by 384
(1992) · PubMed · Cited by 383
A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry
El Hallani, S., Boisselier, B., Peglion, F., Rousseau, A., Colin, C., Idbaih, A., Marie, Y., Mokhtari, K., Thomas, J. L., Eichmann, A., et al. (2010) · Brain · doi:10.1093/brain/awq044 · Cited by 374
Genetic alterations and signaling pathways in the evolution of gliomas
Ohgaki, H., & Kleihues, P. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01308.x · Cited by 355
ten Dijke, P., Ichijo, H., Franzèn, P., Schulz, P. J., Saras, J., Toyoshima, H., Heldin, C., & Miyazono, K. (1993) · PubMed · Cited by 351
Angiogenesis in malignant gliomas
Plate, K. H., & Risau, W. (1995) · Glia · doi:10.1002/glia.440150313 · Cited by 337
Proliferation of human malignant astrocytomas is dependent on Ras activation
Guha, A., Feldkamp, M. M., Lau, N., Boss, G., & Pawson, A. (1997) · Oncogene · doi:10.1038/sj.onc.1201455 · Cited by 337
Ichimura, K., Bondesson, M., Goike, H., Schmidt, E., Moshref, A., & Collins, V. P. (2000) · PubMed · Cited by 333
Reardon, D. A., Egorin, M. J., Quinn, J. A., Rich, J. N., Gururangan, I., Vredenburgh, J. J., Desjardins, A., Sathornsumetee, S., Provenzale, J. M., Herndon, J. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.2185 · Cited by 330
Mao, L., Merlo, A. U., Bedi, G. C., Shapiro, G. I., Edwards, C. D., Rollins, B. J., & Sidransky, D. (1995) · PubMed · Cited by 329
Barak, Y., Gottlieb, E., Juven-Gershon, T., & Oren, M. (1994) · Genes & Development · doi:10.1101/gad.8.15.1739 · Cited by 328 · cited 1×
“Conversely, the transcription of the MDM2 gene is induced by wild-type p53 [116,117].”
BackgroundBMI1 Sustains Human Glioblastoma Multiforme Stem Cell Renewal
Abdouh, M., Facchino, S., Chatoo, W., Balasingam, V., Ferreira, J., & Bernier, G. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.0968-09.2009 · Cited by 326
Mechanism and biological significance of CD44 cleavage
Nagano, O., & Saya, H. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb03179.x · Cited by 325
microRNA-34a is tumor suppressive in brain tumors and glioma stem cells
Guessous, F., Zhang, Y., Kofman, A., Catania, A., Li, Y., Schiff, D., Purow, B., & Abounader, R. (2010) · Cell Cycle · doi:10.4161/cc.9.6.10987 · Cited by 306
Krakstad, C., & Chekenya, M. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-135 · Cited by 301
Guha, A. R., Dashner, K., Black, P. L. M., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910600206 · Cited by 296
Reifenberger, G., REIFENBERGER, J., Ichimura, K., Meltzer, P. S., & Collins, V. P. (1994) · PubMed · Cited by 279
A functional p53-responsive intronic promoter is contained within the human mdm2 gene
Zauberman, A., Flusberg, D., Haupt, Y., Barak, Y., & Oren, M. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.14.2584 · Cited by 276
(2003) · PubMed · Cited by 269
Angiogenesis and invasion in glioma
Onishi, M., Ichikawa, T., Kurozumi, K., & Date, I. (2011) · Brain Tumor Pathology · doi:10.1007/s10014-010-0007-z · Cited by 264
Okamoto, I., Kawano, Y., Tsuiki, H., Sasaki, J.-I., Nakao, M., Matsumoto, M., Suga, M., Ando, M., Nakajima, M., & Saya, H. (1999) · Oncogene · doi:10.1038/sj.onc.1202447 · Cited by 257
Tohma, Y., Gratas, C., Biernat, W., Peraud, A., Fukuda, M., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (1998) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199807000-00005 · Cited by 256
(1997) · PubMed · Cited by 256
Sievert, A. J., Jackson, E. M., Gai, X., Hakonarson, H., Judkins, A. R., Resnick, A. C., Sutton, L. N., Storm, P. B., Shaikh, T. H., & Biegel, J. A. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00225.x · Cited by 255
p53 transcriptional activity is essential for p53-dependent apoptosis following DNA damage
Chao, C. (2000) · The EMBO Journal · doi:10.1093/emboj/19.18.4967 · Cited by 252
Novel anti-angiogenic therapies for malignant gliomas
Norden, A. D., Drappatz, J., & Wen, P. Y. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70260-6 · Cited by 246
EGFR overexpression and radiation response in glioblastoma multiforme
Barker, F. G., Simmons, M. L., Chang, S. M., Prados, M. D., Larson, D. A., Sneed, P. K., Wara, W. M., Berger, M. S., Chen, P., Israel, M. A., et al. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)01609-1 · Cited by 243
Stracker, T. H., Usui, T., & Petrini, J. H. J. (2009) · DNA Repair · doi:10.1016/j.dnarep.2009.04.012 · Cited by 243
Malignant glioma biology: Role for TGF-? in growth, motility, angiogenesis, and immune escape
Platten, M., Wick, W., & Weller, M. (2001) · Microscopy Research and Technique · doi:10.1002/1097-0029(20010215)52:4<401::aid-jemt1025>3.0.co;2-c · Cited by 242
Vajkoczy, P., Knyazev, P., Kunkel, A., Capelle, H.-H., Behrndt, S., von Tengg-Kobligk, H., Kiessling, F., Eichelsbacher, U., Essig, M., Read, T.-A., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510923103 · Cited by 242
Structural analysis of receptor tyrosine kinases
Hubbard, S. R. (1999) · Progress in Biophysics and Molecular Biology · doi:10.1016/s0079-6107(98)00047-9 · Cited by 239
Intracellular Signal Transduction Pathway Proteins As Targets for Cancer Therapy
Adjei, A. A., & Hidalgo, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.648 · Cited by 238
Squatrito, M., Brennan, C. W., Helmy, K., Huse, J. T., Petrini, J. H., & Holland, E. C. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.034 · Cited by 238
p14ARF Deletion and Methylation in Genetic Pathways to Glioblastomas
Nakamura, M., Watanabe, T., Klangby, U., Asker, C., Wiman, K., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (2001) · Brain Pathology · doi:10.1111/j.1750-3639.2001.tb00388.x · Cited by 237
Self-citationEffect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro.
Lund‐Johansen, M., Bjerkvig, R., Humphrey, P. A., Bigner, S. H., Bigner, D. D., & Lærum, O. D. (1990) · PubMed · Cited by 230
Feldkamp, M. M., Feldkamp, M. M., Lala, P., Lau, N., Roncari, L., Guha, A., Guha, A., & Guha, A. (1999) · Neurosurgery · doi:10.1097/00006123-199912000-00034 · Cited by 227
Isocitrate dehydrogenase-1 mutations: A fundamentally new understanding of diffuse glioma?
Kloosterhof, N. K., Bralten, L. B., Dubbink, H. J., French, P. J., & van den Bent, M. J. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70053-x · Cited by 222
Perifosine: Update on a novel Akt inhibitor
Gills, J. J., & Dennis, P. A. (2009) · Current Oncology Reports · doi:10.1007/s11912-009-0016-4 · Cited by 221
Sunayama, J., Matsuda, K.-I., Sato, A., Tachibana, K., Suzuki, K., Narita, Y., Shibui, S., Sakurada, K., Kayama, T., Tomiyama, A., et al. (2010) · Stem Cells · doi:10.1002/stem.521 · Cited by 218 · cited 1×
“Inactivation of either Ras/Raf/MAPK or PI3K/Akt/mTOR triggered activation of the other, suggesting that there may be mutually inhibitory crosstalk between them [79] (Figure 3).”
BackgroundKefas, B., Comeau, L., Floyd, D. H., Seleverstov, O., Godlewski, J., Schmittgen, T., Jiang, J., diPierro, C. G., Li, Y., Chiocca, E. A., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4966-09.2009 · Cited by 216
Yamazaki, H., Fukui, Y., Ueyama, Y., Tamaoki, N., Kawamoto, T., Taniguchi, S., & Shibuya, M. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.4.1816 · Cited by 212
Development of NG2 neural progenitor cells requires Olig gene function
Ligon, K. L., Kesari, S., Kitada, M., Sun, T., Arnett, H. A., Alberta, J. A., Anderson, D. J., Stiles, C. D., & Rowitch, D. H. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511001103 · Cited by 205
Frequent Alterations in the Expression of Serine/Threonine Kinases in Human Cancers
Capra, M., Nuciforo, P. G., Confalonieri, S., Quarto, M., Bianchi, M., Nebuloni, M., Boldorini, R., Pallotti, F., Viale, G., Gishizky, M. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3489 · Cited by 200
Platelet‐derived growth factor in human glioma
Westermark, B., Heldin, C., & Nistér, M. (1995) · Glia · doi:10.1002/glia.440150307 · Cited by 198
IL-6 is required for glioma development in a mouse model
Weissenberger, J., Loeffler, S., Kappeler, A., Kopf, M., Lukes, A., Afanasieva, T. A., Aguzzi, A., & Weis, J. (2004) · Oncogene · doi:10.1038/sj.onc.1207455 · Cited by 189
Lamszus, K., Ulbricht, U., Matschke, J., Brockmann, M. A., Fillbrandt, R., & Westphal, M. (2003) · PubMed · Cited by 189
The p53 gene and its role in human brain tumors
Bögler, O., Su Huang, H. ‐., Kleihues, P., & Cavenee, W. K. (1995) · Glia · doi:10.1002/glia.440150311 · Cited by 187
Mariani, L., Beaudry, C., McDonough, W. S., Hoelzinger, D. B., Demuth, T., Ross, K. R., Berens, T., Coons, S. W., Watts, G., Trent, J. M., et al. (2001) · Journal of Neuro-Oncology · doi:10.1023/a:1012253317934 · Cited by 177
Salhia, B., Rutten, F., Nakada, M., Beaudry, C., Berens, M., Kwan, A., & Rutka, J. T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0160 · Cited by 167
Self-citationAlterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas
Biernat, W., Tohma, Y., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (1997) · Acta Neuropathologica · doi:10.1007/s004010050711 · Cited by 166
Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2
Hu, B., Guo, P., Fang, Q., Tao, H.-Q., Wang, D., Nagane, M., Su Huang, H.-J., Gunji, Y., Nishikawa, R., Alitalo, K., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533394100 · Cited by 164 · cited 1×
“Additionally, EGFR, Tie, and DDR1 signaling induce the expression and activation of MMP-2, which degrades and remodels the ECM surrounding tumor cells [64-66].”
BackgroundProteolytic Cleavage of the CD44 Adhesion Molecule in Multiple Human Tumors
Okamoto, I., Tsuiki, H., Kenyon, L. C., Godwin, A. K., Emlet, D. R., Holgado-Madruga, M., Lanham, I. S., Joynes, C. J., Vo, K. T., Guha, A., et al. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64863-8 · Cited by 160
Role of Synaptojanin 2 in Glioma Cell Migration and Invasion
Chuang, Y.-Y., Tran, N. L., Rusk, N., Nakada, M., Berens, M. E., & Symons, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2097 · Cited by 159
Self-citationOhgaki, H., Watanabe, K., Tachibana, O., Sato, K., & Kleihues, P. (1996) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199605000-00017 · Cited by 155
Predominant Expression of Mutant EGFR (EGFRvIII) is Rare in Primary Glioblastomas
Biernat, W., Huang, H., Yokoo, H., Kleihues, P., & Ohgaki, H. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00045.x · Cited by 152
Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications
Gottfried, O. N., Viskochil, D. H., & Couldwell, W. T. (2009) · Neurosurgical FOCUS · doi:10.3171/2009.11.focus09221 · Cited by 150
An RNAi Screen Identifies TRRAP as a Regulator of Brain Tumor-Initiating Cell Differentiation
Wurdak, H., Zhu, S., Romero, A., Lorger, M., Watson, J., Chiang, C.-Y., Zhang, J., Natu, V. S., Lairson, L. L., Walker, J. R., et al. (2010) · Cell stem cell · doi:10.1016/j.stem.2009.11.002 · Cited by 149
Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma
Salmaggi, A., Eoli, M., Frigerio, S., Silvani, A., Gelati, M., Corsini, E., Broggi, G., & Boiardi, A. (2003) · Journal of Neuro-Oncology · doi:10.1023/a:1023367223575 · Cited by 149
Ram, R. R., Lorente, G., Nikolich, K., Urfer, R., Foehr, E. D., & Nagavarapu, U. (2005) · Journal of Neuro-Oncology · doi:10.1007/s11060-005-6874-1 · Cited by 142
Characterization of p53 and p21 Functional Interactions in Glioma Cells en Route to Apoptosis
Gomez‐Manzano, C., Fueyo-Margareto, J., Kyritsis, A. P., Steck, P. A., Levin, V. A., Yung, W. K. A., & McDonnell, T. J. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.14.1036 · Cited by 142
Reardon, D. A., Dresemann, G. P., Taillibert, S., Campone, M., van den Bent, M. J., Clément, P. M., Blomquist, E., Gordower, L., Schultz, H., Raizer, J. J., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605411 · Cited by 141
Ramnarain, D. B., Park, S., Lee, D. Y., Hatanpaa, K. J., Scoggin, S. O., Otu, H., Libermann, T. A., Raisanen, J. M., Ashfaq, R., Wong, E. T., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2753 · Cited by 140
Targeting SRC in glioblastoma tumors and brain metastases: Rationale and preclinical studies
Ahluwalia, M. S., de Groot, J., Liu, W., & Gladson, C. L. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.08.014 · Cited by 139
Loss of P16INK4 expression is frequent in high grade gliomas.
Nishikawa, R., Furnari, F. B., Lin, H., Arap, W., Berger, M. S., Cavenee, W. K., & Huang, H. (1995) · PubMed · Cited by 139
Targeting A20 Decreases Glioma Stem Cell Survival and Tumor Growth
Hjelmeland, A. B., Wu, Q., Wickman, S., Eyler, C. E., Heddleston, J. M., Shi, Q., Lathia, J. D., MacSwords, J., Lee, J., McLendon, R. E., et al. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000319 · Cited by 138
Zagzag, D., Friedlander, D. R., Dosik, J., Chickramane, S., Chan, W., GRECO, M. A., Allen, J. C., Dorovini‐Zis, K., & Grumet, M. (1996) · PubMed · Cited by 135
Tumour angiogenesis: Its mechanism and therapeutic implications in malignant gliomas
Wong, M. L. H., Prawira, A., Kaye, A. H., & Hovens, C. M. (2009) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2009.02.009 · Cited by 130
Malignant Glioma Physiology: Cellular Response to Hypoxia and Its Role in Tumor Progression
Brat, D. J., & Mapstone, T. B. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-8-200304150-00014 · Cited by 128
Association of EGFR Gene Amplification and CDKN2 (p16/MTS1) Gene Deletion in Glioblastoma Multiforme
Hayashi, Y., Ueki, K., Waha, A., Wiestler, O. D., Louis, D. N., & von Deimling, A. (1997) · Brain Pathology · doi:10.1111/j.1750-3639.1997.tb00890.x · Cited by 128
Self-citationDiffuse brain invasion of glioma cells requires beta 1 integrins.
Paulus, W., Baur, I., Beutler, A. S., & Reeves, S. A. (1996) · PubMed · Cited by 126
Angiogenesis as a Therapeutic Target in Malignant Gliomas
Chi, A. S., Sorensen, A. G., Jain, R. K., & Batchelor, T. T. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0272 · Cited by 121
Molecular Genetic Correlates of p16, cdk4, and pRb Immunohistochemistry in Glioblastomas
Burns, K. L., Ueki, K., Jhung, S., Koh, J., & Louis, D. N. (1998) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199802000-00003 · Cited by 120
Recent developments in neurofibromatosis type 1
Lee, M., & Stephenson, D. A. (2007) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3280895da8 · Cited by 120
Amplification and overexpression of the egf receptor gene in primary human glioblastomas
Libermann, T. A., Nusbaum, H. R., Razon, N., Kris, R., Lax, I., Soreq, H., Whittle, N., Waterfield, M. D., Ullrich, A., & Schlessinger, J. (1985) · Journal of Cell Science · doi:10.1242/jcs.1985.supplement_3.16 · Cited by 119
Hirata, A., Hosoi, F., Miyagawa, M., Ueda, S.-I., Naito, S., Fujii, T., Kuwano, M., & Ono, M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2748 · Cited by 109
Morrison, R. S., Yamaguchi, F., Bruner, J. M., Tang, M., Wl, M., & Berger, M. S. (1994) · PubMed · Cited by 105
Belot, N., Rorive, S., Doyen, I., Lefranc, F., Bruyneel, E. A., Dedecker, R., Micik, S., Brotchi, J., Decaestecker, C., Salmon, I. J., et al. (2001) · Glia · doi:10.1002/glia.1124 · Cited by 105
Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome
Watanabe, T., Vital, A., Nobusawa, S., Kleihues, P., & Ohgaki, H. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0528-x · Cited by 102
Self-citationPIK3CA alterations in primary (de novo) and secondary glioblastomas
Kita, D., Yonekawa, Y., Weller, M., & Ohgaki, H. (2007) · Acta Neuropathologica · doi:10.1007/s00401-006-0186-1 · Cited by 100
Self-citationMutation analysis of B-RAF gene in human gliomas
Basto, D., Trovisco, V., Lopes, J. M., Martins, A. M., Pardal, F., Soares, P., & Reis, R. M. (2004) · Acta Neuropathologica · doi:10.1007/s00401-004-0936-x · Cited by 90
Shibuya, M. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07175.x · Cited by 86
Su, Y., Li, G., Zhang, X., Gu, J., Zhang, C., Tian, Z., & Zhang, J. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.8.6263 · Cited by 83
CD44 expression in human gliomas
Ranuncolo, S. M., Ladeda, V., Specterman, S., Varela, M. S., Lastiri, J. M., Morandi, A., Matos, E., Joffé, E. B. D. K., Puricelli, L., & Pallotta, M. G. (2001) · Journal of Surgical Oncology · doi:10.1002/jso.10045 · Cited by 76
Uncovering Therapeutic Targets FOR Glioblastoma: A Systems Biology Approach
Huang, P. H., Cavenee, W. K., Furnari, F. B., & White, F. M. (2007) · Cell Cycle · doi:10.4161/cc.6.22.4922 · Cited by 72
EGFRMutations and Sensitivity to Gefitinib
Rossi, G., Marchioni, A., & Longo, L. (2004) · New England Journal of Medicine · doi:10.1056/nejm200409163511221 · Cited by 72
Hegi, M. E., Hausen, A. Z., Rüedi, D., Malin, G., & Kleihues, P. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970926)73:1<57::aid-ijc10>3.0.co;2-2 · Cited by 59
The p21-Ras signal transduction pathway and growth regulation in human high-grade gliomas
Bredel, M., & Pollack, I. F. (1999) · Brain Research Reviews · doi:10.1016/s0165-0173(98)00057-5 · Cited by 57
NF-κB controls growth of glioblastomas/astrocytomas
Smith, D. L., Shimamura, T., Barbera, S., & Bejcek, B. E. (2007) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-007-9593-4 · Cited by 57
Receptor Tyrosine Kinase Signaling In Gliomagenesis: Pathobiology And Therapeutic Approaches
Kapoor, G. S., & O’Rourke, D. M. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.2.4.507 · Cited by 56
Leung, S. Y., Yuen, S. T., Chan, T. L., Chan, A. S. Y., Ho, J. W. C., Kwan, K., Fan, Y. W., Hung, K. N., Chung, L.-P., & Wyllie, A. H. (2000) · Oncogene · doi:10.1038/sj.onc.1203740 · Cited by 51
Murphy, G. M., Lee, Y. L., Jia, X., et al. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.65062716.x · Cited by 34
Antiangiogenic Strategies for Treatment of Malignant Gliomas
Chi, A. S., Norden, A. D., & Wen, P. Y. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.04.010 · Cited by 32
Absence of AKT1 Mutations in Glioblastoma
Bleeker, F. E., Lamba, S., Zanon, C., van Tilborg, A. A., Leenstra, S., Troost, D., Hulsebos, T. J. M., Vandertop, W. P., & Bardelli, A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005638 · Cited by 32
CHEK2 mutations in primary glioblastomas
Sallinen, S., konen, T., Haapasalo, H. K., & Schleutker, J. (2005) · Journal of Neuro-Oncology · doi:10.1007/s11060-005-5953-7 · Cited by 26
Apoptosis and proliferation: correlation with p53 in astrocytic tumours
Sarkar, C., Karak, A. K., Nath, N., Sharma, M. C., Mahapatra, A. K., Chattopadhyay, P., & Sinha, S. (2005) · Journal of Neuro-Oncology · doi:10.1007/s11060-004-3015-1 · Cited by 21
Clinical Importance of c-Met Protein Expression in High Grade Astrocytic Tumors
Hirose, Y., Kojima, M., Sagoh, M., Hayashi, T., MURAKAMI, H., SHIMAZAKI, K., Yoshida, K., & KAWASE, T. (1998) · Neurologia medico-chirurgica · doi:10.2176/nmc.38.851 · Cited by 15
2010: neuro-oncology is moving!
Stupp, R., & Weller, M. (2010) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3283407eed · Cited by 12
Cited by
Hanif, F., Muzaffar, K., Perveen, K., Malhi, S. M., & Sımjee, S. U. (2017) · PubMed · doi:10.22034/apjcp.2017.18.1.3 · Cited by 1,231
Targeting cellular pathways in glioblastoma multiforme
Pearson, J. R. D., & Regad, T. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.40 · Cited by 344
Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives
Szopa, W., Burley, T. A., Kramer-Marek, G., & Kaspera, W. (2017) · BioMed Research International · doi:10.1155/2017/8013575 · Cited by 320
Molecular and Genomic Alterations in Glioblastoma Multiforme
Crespo, I., Vital, A. L., Gonzalez-Tablas, M., Patino, M. D. C., Otero, A., Lopes, M. C., de Oliveira, C., Domingues, P., Orfao, A., & Tabernero, M. D. (2015) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.02.023 · Cited by 225
mTOR-Dependent Cell Proliferation in the Brain
Ryskalin, L., Lazzeri, G., Flaibani, M., Biagioni, F., Gambardella, S., Frati, A., & Fornai, F. (2017) · BioMed Research International · doi:10.1155/2017/7082696 · Cited by 86
“The biology of glioblastoma is characterized by prominent proliferation, active invasiveness, and rich angiogenesis, mainly due to highly mutated and/or deregulated signaling pathways within the tumor [146, 147].”
Background
Metadata
- Authors
- Nakada, M., Kita, D., Watanabe, T., Hayashi, Y., Teng, L., Pyko, I. V., & Hamada, J.-I.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2011-08-10
- Volume
- 3
- Issue
- 3
- Pages
- 3242-3278
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W1977657574
- Cited by
- 264
- References
- 180
- FWCI
- 3.32
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.